Carregando...
Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours
Overactivation of the mitogen-activated protein kinase (MAPK) pathway is an important driver of many human cancers. First line, FDA-approved therapies targeting MAPK signalling, which include BRAF and MEK inhibitors, have variable success across cancers, and a significant number of patients quickly...
Na minha lista:
| Publicado no: | J Oncol |
|---|---|
| Principais autores: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7199609/ https://ncbi.nlm.nih.gov/pubmed/32411231 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/1079827 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|